# Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.

> **NCT07421856** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Multiple Myeloma in Relapse
- Multiple Myeloma Refractory

## Interventions

- **BIOLOGICAL:** Autologous BCMA-targeting CAR T cells

## Key facts

- **NCT ID:** NCT07421856
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-02-01
- **Final completion:** 2030-02-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07421856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07421856, "Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07421856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*